CASI Pharmaceuticals Inc. (NASDAQ: CASI) reported additional results from its Phase 1 study of CID-103 in adult patients with chronic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE